




Instance: composition-en-d702c645ce8960ab36c7968fd9f89bfc
InstanceOf: CompositionUvEpi
Title: "Composition for enrylaze Package Leaflet"
Description:  "Composition for enrylaze Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp1b4c40352fad33893373edfe0b062c8a)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - enrylaze"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Enrylaze is and what it is used for  </li>
<li>What you need to know before you are given Enrylaze </li>
<li>How Enrylaze is given  </li>
<li>Possible side effects  </li>
<li>How Enrylaze is stored </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What enrylaze is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What enrylaze is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Enrylaze contains the active substance recombinant crisantaspase. It is a medicine used alongside 
other medicines to treat acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL). 
Enrylaze can be given to patients aged 1 months of age or older.<br />
Enrylaze contains a protein made in the laboratory by recombinant DNA technology. This protein 
works by decreasing the amount of a protein called asparagine. This protein is needed by the ALL and 
LBL cancer cells to survive. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take enrylaze"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take enrylaze"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>You should not receive Enrylaze<br />
* if you have a severe allergic reaction to Enrylaze. 
* if you have an allergic reaction to any of the other ingredients of this medicine (listed in<br />
section 6). 
* if you are currently experiencing severe pancreatitis (inflammation of the pancreas). 
* if you have experienced severe pancreatitis after being treated with asparaginase therapies. 
* if you have experienced serious blood clots after being treated with asparaginase therapies. 
* if you have experienced serious bleeding events after being treated with asparaginase therapies. </p>
<p>Warnings and precautions<br />
Talk to your doctor or pharmacist before you receive Enrylaze. </p>
<p>The following problems may occur during treatment with Enrylaze: 
* serious allergic reactions that may be life threatening. The hospital will ensure they are prepared 
to address any allergic reactions that may occur during treatment. 
* inflammation of your pancreas. Discomfort or pain in your stomach or back area may be a sign 
of pancreatitis and should be reported to your doctor straight away. 
* changes in your body s ability to manage blood sugar levels. Your doctor should monitor your 
glucose levels whilst on treatment and provide insulin if necessary. 
* unusual bleeding events or blood clots. If either of these events occur treatment will be paused 
by your doctor until they are resolved. 
* issues with your liver. Your doctor will monitor you to identify if you are experiencing any 
issues with your liver and treat you as necessary.<br />
* central nervous system toxicity, such as seizures and impaired neurological function. Also, 
instances of posterior reversible encephalopathy syndrome (characterised by headache, 
confusion, seizures and loss of vision) may require blood-pressure lowering medicines and in 
case of seizure, treatment with anti-epileptic medicines. </p>
<p>Monitoring during treatment with Enrylaze 
You will be monitored during and after treatment with Enrylaze for: 
* allergic reactions 
* functioning of your pancreas and liver 
* blood sugar levels </p>
<p>Other medicines and Enrylaze 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. In particular inform your doctor or pharmacist if you have or are receiving: 
* methotrexate or cytarabine, used in cancer treatment. Use of these medicines immediately 
before Enrylaze may increase their effect. 
* vincristine, used in cancer treatment. Use of vincristine with Enrylaze may increase the toxicity 
of vincristine. 
* glucocorticoids, used as anti-inflammation medicines. Use of these medicines immediately 
before Enrylaze may increase the formation of blood clots.  </p>
<p>Pregnancy 
Enrylaze should not be used during pregnancy, and women should check they are not pregnant prior to 
starting therapy. If you are pregnant or think you may be pregnant, ask your doctor or pharmacist for 
advice before receiving this medicine. </p>
<p>Breast-feeding 
You should not breast-feed during treatment and for two weeks following treatment with Enrylaze, as 
there may be a risk to the breast-feeding child. </p>
<p>Family planning 
Both men and women should use a form of contraception and avoid conceiving a child during 
treatment with Enrylaze and for 3 months after you last receive Enrylaze. Hormonal contraceptives are 
not recommended for use in women when being treated with Enrylaze. </p>
<p>Women should undergo pregnancy testing before starting treatment. </p>
<p>Driving and using machines 
Enrylaze can cause you to feel sick and have a headache. This may impact your ability to drive and 
operate machines. </p>
<p>Enrylaze contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per dose unit, that is to say essentially 
 sodium free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take enrylaze"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take enrylaze"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Your doctor will determine what dose you are given and whether it will be given to you by an infusion 
into your veins or an injection into your muscle. You may also be given some other medicines before 
you start receiving Enrylaze, such as paracetamol, H1 and H2 blocker. </p>
<p>The dose and how it is given may vary depending on your specific condition, body surface area and 
response to therapy.  </p>
<p>If you are given Enrylaze into your veins, this will be given over a 2-hour period. If you are given 
Enrylaze into a muscle, several injection sites may be used. </p>
<p>If you think you have been given more Enrylaze than you should 
If you have any concerns, contact your doctor or any healthcare professional immediately. </p>
<p>If you think you have missed a dose of Enrylaze 
If you have any concerns, contact your doctor or any healthcare professional immediately. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. For 
patients treated with Enrylaze the following side effects were reported. </p>
<p>Serious side effects 
Tell your doctor immediately if you experience: 
Symptoms of a serious allergic reaction, including swelling of the face, shortness of breath, hay fever 
like symptoms, rash, chills, wheezing, flushing, vomiting, high or low blood pressure. In severe cases 
anaphylaxis (a sudden, severe allergic reaction with breathing difficulty, swelling, 
light-headedness, fast heartbeat, sweating and loss of consciousness) can also occur. </p>
<p>Symptoms of blood clots, including in the blood vessels of the lung which could present as sudden 
shortness of breath, chest pain, or coughing up blood and the blood vessels of the brain which could 
present with symptoms such as weakness/numbness, seizure, trouble speaking, or severe headache.  </p>
<p>Symptoms of pancreatitis, including abdominal pain, nausea, vomiting, back pain, or loss of appetite. </p>
<p>Other side effects 
Talk to your doctor if you get any of the following: </p>
<p>Very common side effects (may affect more than 1 in 10 people): 
* allergic reaction, including rash, itching, and hives 
* infections 
* low levels of red blood cells (anaemia) 
* low levels of blood platelets (thrombocytopenia) 
* low levels of white blood cells (white blood cell count decreased) 
* low levels of neutrophils, a type of white blood cell that fights off infection (neutropenia) 
* low levels of white blood cells (neutrophils) with fever due to infection (febrile neutropenia)<br />
* low levels of lymphocytes, a type of white blood cell that fights off infection (lymphocyte count 
decreased) 
* pain in your stomach (abdominal pain) 
* diarrhoea 
* feeling sick (nausea) 
* vomiting 
* tiredness (fatigue) 
* fever (pyrexia) 
* high blood sugar levels (hyperglycaemia) 
* pain in limbs (pain in extremity) 
* weight loss (weight decreased) 
* headache 
* decreased appetite 
* abnormal liver function test (transaminases increased, blood bilirubin increased) 
* decreased albumin (a blood protein) level (hypoalbuminaemia) 
* anxiety 
* bruising (contusion) </p>
<p>Common side effects (may affect up to 1 in 10 people): 
* blood poisoning (sepsis)<br />
<em> sudden, severe allergic reaction with breathing difficulty, swelling, lightheadedness, fast 
heartbeat, sweating and loss of consciousness (anaphylactic reaction) 
* skin rash characterized with flat, discolored patches (macules) and raised, reddened bumps 
(papules) (rash maculo-papular) 
* skin rash with redness and inflamation (rash erythematous) 
* hives (urticaria) 
* itchy skin (pruritus) 
* inflammation of the pancreas (pancreatitis) 
* injection site pain<br />
</em> injection site reaction 
* infusion related reactions 
* abnormal blood clotting factor levels (prolonged activated partial thromboplastin time, 
decreased antithrombin III, decreased blood fibrinogen) 
* abnormal kidney function (increased blood creatinine) 
* low blood sugar levels (hypoglycaemia) 
* low blood pressure (hypotension) 
* blood clots, including in the blood vessels of the lung and brain 
* irritability 
* dizziness </p>
<p>Uncommon side effects (may affect up to 1 in 100 people) 
* blood clot in a major brain vein (superior sagittal sinus thrombosis) 
* blood clot in the neck vein (jugular vein thrombosis) 
* blood clot in extremity veins (deep vein thrombosis) </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store enrylaze"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store enrylaze"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and vial after EXP. The 
expiry date refers to the last day of that month. </p>
<p>Store the unopened vials in a refrigerator (2  C 8  C) in an upright position. Do not freeze. Keep the 
vial in the outer carton in order to protect from light. </p>
<p>After preparing a dose in a syringe, Enrylaze can be stored for up to 8 hours at room temperature 
(15  C 25  C) or 24 hours when refrigerated (2  C 8  C).  </p>
<p>After dilution in an intravenous bag, Enrylaze can be stored for up to 12 hours at room temperature 
(15  C 25  C) or 24 hours when refrigerated (2  C 8  C). Storage time starts once the solution has 
been withdrawn from the unopened vials. </p>
<p>Do not use this medicine if you notice any particles in the solution. </p>
<p>Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines 
you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Enrylaze contains<br />
* The active substance is recombinant crisantaspase. Each vial contains 10 mg of recombinant 
crisantaspase in 0.5 mL solution. 
* The other ingredients are trehalose dihydrate, sodium chloride (see section 2  Enrylaze contains 
sodium ), sodium hydroxide (for pH adjustment), disodium phosphate, sodium dihydrogen 
phosphate monohydrate, polysorbate 80 and water for injections. </p>
<p>What Enrylaze looks like and contents of the pack 
Enrylaze is a clear to slightly yellow solution for injection/infusion, free from particulate matter. </p>
<p>One carton contains 3 glass vials, each with 0.5 mL of solution for injection/infusion. </p>
<p>Marketing Authorisation Holder and Manufacturer 
Jazz Pharmaceuticals Ireland Ltd<br />
5th Floor 
Waterloo Exchange 
Waterloo Road 
Dublin 4 
D04 E5W7 
Ireland 
Tel: +353 1 968 1Email: medinfo-int@jazzpharma.com </p>
<p>This leaflet was last revised in:  </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-d702c645ce8960ab36c7968fd9f89bfc
InstanceOf: CompositionUvEpi
Title: "Composition for enrylaze Package Leaflet"
Description:  "Composition for enrylaze Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp1b4c40352fad33893373edfe0b062c8a)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - enrylaze"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse  </li>
<li>Det skal du vide, før du begynder at få Enrylaze </li>
<li>Sådan får du Enrylaze  </li>
<li>Bivirkninger  </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What enrylaze is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What enrylaze is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Enrylaze indeholder det aktive stof rekombinant crisantaspase. Det er et lægemiddel, der anvendes 
sammen med andre lægemidler til behandling af akut lymfoblastær leukæmi (ALL) og lymfoblastært 
lymfom (LBL). Enrylaze kan gives til patienter i alderen 1 måned og derover. 
Enrylaze indeholder et protein, der er fremstillet i laboratoriet ved rekombinant DNA-teknologi. Dette 
protein virker ved at reducere mængden af et protein, der kaldes asparagin. Dette protein skal ALL- og 
LBL-kræftcellerne bruge for at overleve. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take enrylaze"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take enrylaze"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du må ikke få Enrylaze </p>
<ul>
<li>
<p>hvis du får en alvorlig allergisk reaktion på Enrylaze. </p>
</li>
<li>
<p>hvis du får en allergisk reaktion på et af de øvrige indholdsstoffer i dette lægemiddel (angivet i 
punkt 6). </p>
</li>
<li>
<p>hvis du i øjeblikket har svær pankreatitis (betændelse i bugspytkirtlen). </p>
</li>
<li>
<p>hvis du har haft svær pankreatitis efter behandling med asparaginaseterapi. </p>
</li>
<li>
<p>hvis du har haft alvorlige blodpropper efter behandling med asparaginaseterapi. </p>
</li>
<li>
<p>hvis du har haft alvorlige blødningshændelser efter behandling med asparaginaseterapi. </p>
</li>
</ul>
<p>Advarsler og forsigtighedsregler<br />
Kontakt lægen eller apotekspersonalet, før du får Enrylaze. </p>
<p>Følgende problemer kan opstå under behandling med Enrylaze: </p>
<ul>
<li>alvorlige allergiske reaktioner, der kan være livstruende. Hospitalet vil sikre, at de er klar til at </li>
</ul>
<p>håndtere eventuelle allergiske reaktioner, som måtte opstå under behandlingen. </p>
<ul>
<li>
<p>betændelse i bugspytkirtlen. Ubehag eller smerter i mave- eller rygområdet kan være et tegn på 
pankreatitis og skal straks rapporteres til din læge. </p>
</li>
<li>
<p>ændringer i kroppens evne til at regulere blodsukkerniveauet. Din læge skal overvåge dit 
blodsukkerniveau under behandlingen og om nødvendigt give dig insulin. </p>
</li>
<li>
<p>usædvanlige blødningshændelser eller blodpropper. Hvis en af disse hændelser opstår, vil 
behandlingen blive afbrudt af lægen, indtil problemet er løst. </p>
</li>
<li>
<p>problemer med din lever. Din læge vil overvåge dig for at kontrollere, om du har nogen 
problemer med leveren, og behandle dig efter behov.  </p>
</li>
<li>
<p>toksicitet i centralnervesystemet, såsom krampeanfald og nedsat neurologisk funktion. Tilfælde 
af posteriort reversibelt encefalopatisyndrom (kendetegnet ved hovedpine, forvirring, 
krampeanfald og synstab) kan også kræve blodtrykssænkende medicin, og i tilfælde af 
krampeanfald kan det være nødvendigt at behandle med epilepsimedicin. </p>
</li>
</ul>
<p>Overvågning under behandling med Enrylaze 
Under og efter behandlingen med Enrylaze vil du blive overvåget for: </p>
<ul>
<li>
<p>allergiske reaktioner </p>
</li>
<li>
<p>funktion af din bugspytkirtel og lever </p>
</li>
<li>
<p>blodsukkerniveau. </p>
</li>
</ul>
<p>Brug af andre lægemidler sammen med Enrylaze 
Fortæl lægen eller apotekspersonalet, hvis du tager andre lægemidler, for nylig har taget andre 
lægemidler eller planlægger at tage andre lægemidler. Fortæl det især til lægen eller 
apotekspersonalet, hvis du har fået eller får: </p>
<ul>
<li>
<p>methotrexat eller cytarabin, som bruges inden for kræftbehandling. Hvis disse lægemidler 
anvendes umiddelbart før Enrylaze, kan deres virkning blive stærkere. </p>
</li>
<li>
<p>vincristin, bruges inden for kræftbehandling. Anvendelse af vincristin sammen med Enrylaze 
kan øge toksiciteten af vincristin. </p>
</li>
<li>
<p>glukokortikoider, bruges som antiinflammatoriske lægemidler. Hvis disse lægemidler anvendes 
umiddelbart før Enrylaze, kan det øge dannelsen af blodpropper.  </p>
</li>
</ul>
<p>Graviditet 
Enrylaze må ikke anvendes under graviditet, og kvinder skal kontrollere, at de ikke er gravide, inden 
behandlingen påbegyndes. Hvis du er gravid eller har mistanke om, at du er gravid, skal du spørge din 
læge eller apotekspersonalet til råds, før du får dette lægemiddel. </p>
<p>Amning 
Du må ikke amme under behandlingen og i to uger efter behandlingen med Enrylaze. Der kan være en 
risiko for det ammede barn. </p>
<p>Familieplanlægning 
Både mænd og kvinder skal anvende en form for prævention og undgå at undfange et barn under 
behandlingen med Enrylaze og i 3 måneder efter den sidste dosis Enrylaze. Kvinder frarådes at bruge 
hormonel prævention under behandling med Enrylaze. </p>
<p>Kvinder skal have foretaget en graviditetstest, inden behandlingen indledes. </p>
<p>Trafik- og arbejdssikkerhed 
Enrylaze kan give dig kvalme og hovedpine. Dette kan påvirke din evne til at føre motorkøretøj og 
betjene maskiner. </p>
<p>Enrylaze indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. dosisenhed, dvs. det er i det 
væsentlige natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take enrylaze"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take enrylaze"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Din læge vil bestemme, hvilken dosis du får, og om den vil blive givet til dig som infusion i 
blodårerne eller som en injektion i en muskel. Du kan også få andre lægemidler, inden du begynder at 
få Enrylaze, såsom paracetamol, H1- og H2-blokker.  </p>
<p>Dosis og hvordan den gives kan variere afhængigt af din specifikke tilstand, din krops overfladeareal 
og din reaktion på behandlingen.  </p>
<p>Hvis du får Enrylaze i blodårerne, vil det blive givet over en periode på 2 timer. Hvis du får Enrylaze i 
en muskel, kan der blive anvendt flere injektionssteder. </p>
<p>Hvis du tror, at du har fået for meget Enrylaze 
Hvis du er bekymret, skal du straks kontakte lægen eller en anden sundhedsperson. </p>
<p>Hvis du tror, at du har glemt at få en dosis Enrylaze 
Hvis du er bekymret, skal du straks kontakte lægen eller en anden sundhedsperson. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. 
Følgende bivirkninger er blevet indberettet for patienter, som blev behandlet med Enrylaze. </p>
<p>Alvorlige bivirkninger 
Fortæl det straks til lægen, hvis du oplever: 
Symptomer på en alvorlig allergisk reaktion, herunder hævelse i ansigtet, åndenød, høfeberlignende 
symptomer, udslæt, kulderystelser, hvæsende vejrtrækning, rødme, opkastning, for højt eller for lavt 
blodtryk. I alvorlige tilfælde kan der også opstå anafylaksi (en pludselig, alvorlig allergisk reaktion 
med vejrtrækningsbesvær, hævelse, ørhed, hurtig puls, sveden og bevidsthedstab). </p>
<p>Symptomer på blodpropper, herunder i blodkarrene i lungerne, der kan vise sig som pludselig 
åndenød, brystsmerter, eller at du hoster blod op, og i blodkarrene i hjernen, der kan vise sig med 
symptomer såsom svaghed/følelsesløshed, krampeanfald, besvær med at tale eller svær hovedpine. </p>
<p>Symptomer på pankreatitis, herunder mavesmerter, kvalme, opkastning, rygsmerter eller mistet 
appetit. </p>
<p>Andre bivirkninger 
Kontakt lægen, hvis du får noget af følgende: </p>
<p>Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 personer): </p>
<ul>
<li>
<p>allergisk reaktion, herunder udslæt, kløe og nældefeber </p>
</li>
<li>
<p>infektioner </p>
</li>
<li>
<p>lavt niveau af røde blodlegemer (anæmi) </p>
</li>
<li>
<p>lavt niveau af blodplader (trombocytopeni) </p>
</li>
<li>
<p>lavt niveau af hvide blodlegemer (nedsat antal hvide blodlegemer) </p>
</li>
<li>
<p>lavt niveau af neutrofiler, en type hvide blodlegemer, der bekæmper infektioner (neutropeni) </p>
</li>
<li>
<p>lavt niveau af hvide blodlegemer (neutrofiler) samt feber på grund af infektion (febril 
neutropeni) </p>
</li>
<li>
<p>lavt niveau af lymfocytter, en type hvide blodlegemer, der bekæmper infektioner (nedsat 
lymfocyttal) </p>
</li>
<li>
<p>mavesmerter (abdominalsmerter) </p>
</li>
<li>
<p>diarré </p>
</li>
<li>
<p>kvalme </p>
</li>
<li>
<p>opkastning </p>
</li>
<li>
<p>træthed (fatigue) </p>
</li>
<li>
<p>feber (pyreksi) </p>
</li>
<li>
<p>højt blodsukkerniveau (hyperglykæmi) </p>
</li>
<li>
<p>smerter i arme og ben (smerter i ekstremiteter) </p>
</li>
<li>
<p>vægttab (lavere vægt) </p>
</li>
<li>
<p>hovedpine </p>
</li>
<li>
<p>nedsat appetit </p>
</li>
<li>
<p>unormal leverfunktionstest (forhøjede transaminaser, forhøjet bilirubin i blodet) </p>
</li>
<li>
<p>nedsat albuminniveau (et blodprotein) (hypoalbuminæmi) </p>
</li>
<li>
<p>angst </p>
</li>
<li>
<p>blå mærker (kontusion). </p>
</li>
</ul>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 personer): </p>
<ul>
<li>
<p>blodforgiftning (sepsis) </p>
</li>
<li>
<p>pludselig, alvorlig allergisk reaktion med vejrtrækningsbesvær, hævelse, ørhed, hurtig puls, 
sveden og bevidsthedstab (anafylaktisk reaktion) </p>
</li>
<li>
<p>hududslæt kendetegnet ved flade, misfarvede pletter (makulae) og hævede, rødlige knopper 
(papler) (makulopapuløst udslæt) </p>
</li>
<li>
<p>hududslæt med rødme og betændelse (erytematøst udslæt) </p>
</li>
<li>
<p>nældefeber (urticaria) </p>
</li>
<li>
<p>kløende hud (pruritus) </p>
</li>
<li>
<p>betændelse i bugspytkirtlen (pankreatitis) </p>
</li>
<li>
<p>smerter på injektionsstedet </p>
</li>
<li>
<p>reaktion på injektionsstedet </p>
</li>
<li>
<p>infusionsrelaterede reaktioner </p>
</li>
<li>
<p>unormale niveauer af blodstørkningsfaktor (forlænget aktiveret partiel tromboplastintid, nedsat 
antitrombin III, nedsat fibrinogen i blodet) </p>
</li>
<li>
<p>unormal nyrefunktion (forhøjet kreatinin i blodet)  </p>
</li>
<li>
<p>lavt blodsukkerniveau (hypoglykæmi) </p>
</li>
<li>
<p>lavt blodtryk (hypotension) </p>
</li>
<li>
<p>blodpropper, herunder i blodkar i lunger og hjerne </p>
</li>
<li>
<p>irritabilitet </p>
</li>
<li>
<p>svimmelhed. </p>
</li>
</ul>
<p>Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 personer): </p>
<ul>
<li>
<p>blodprop i stor hjernevene (superior sagittal sinustrombose) </p>
</li>
<li>
<p>blodprop i halsvene (trombose i vena jugularis) </p>
</li>
<li>
<p>blodprop i ekstremitetsvener (dyb venetrombose). </p>
</li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store enrylaze"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store enrylaze"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på æsken og hætteglasset efter EXP. Udløbsdatoen 
er den sidste dag i den nævnte måned. </p>
<p>De uåbnede hætteglas opbevares i køleskab (2 °C - 8 °C) i opretstående stilling. Må ikke nedfryses. </p>
<p>Opbevar hætteglasset i den ydre karton for at beskytte mod lys. </p>
<p>Efter klargøring af en dosis i sprøjten kan Enrylaze opbevares i op til 8 timer ved stuetemperatur 
(15 °C - 25 °C) eller 24 timer ved opbevaring i køleskab (2 °C - 8 °C).  </p>
<p>Efter fortynding i en intravenøs pose kan Enrylaze opbevares i op til 12 timer ved stuetemperatur 
(15 °C - 25 °C) eller 24 timer ved opbevaring i køleskab (2 °C - 8 °C). Opbevaringstiden begynder, 
når opløsningen er trukket op af de uåbnede hætteglas.  </p>
<p>Brug ikke lægemidlet, hvis du bemærker partikler i opløsningen. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe lægemiddelrester. Af hensyn til miljøet må du 
ikke smide lægemiddelrester i afløbet eller toilettet. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Enrylaze indeholder: </p>
<ul>
<li>
<p>Aktivt stof: rekombinant crisantaspase. Hvert hætteglas indeholder 10 mg rekombinant 
crisantaspase i 0,5 ml opløsning. </p>
</li>
<li>
<p>Øvrige indholdsstoffer: trehalosedihydrat, natriumchlorid (se punkt 2 “Enrylaze indeholder 
natrium"), natriumhydroxid (til pH-justering), dinatriumphosphat, 
natriumdihydrogenphosphatmonohydrat, polysorbat 80 og vand til injektionsvæsker. </p>
</li>
</ul>
<p>Udseende og pakningsstørrelser 
Enrylaze er en klar til let gullig injektions-/infusionsvæske, opløsning, der er fri for partikler. </p>
<p>Én æske indeholder 3 hætteglas af glas, hvert med 0,5 ml injektions-/infusionsvæske, opløsning. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller 
Jazz Pharmaceuticals Ireland Ltd<br />
5th Floor 
Waterloo Exchange 
Waterloo Road 
Dublin 4 
D04 E5W7 
Irland 
Tlf.: +353 1 968 1E-mail: medinfo-int@jazzpharma.com </p>
<p>Denne indlægsseddel blev senest ændret:  </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. Der er også links til andre websteder om sjældne sygdomme 
og om, hvordan de behandles. </p>
<p>Denne indlægsseddel findes på alle EU-/EØS-sprog på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-d702c645ce8960ab36c7968fd9f89bfc
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for enrylaze Package Leaflet for language en"
Description: "ePI document Bundle for enrylaze Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-d702c645ce8960ab36c7968fd9f89bfc"
* entry[0].resource = composition-en-d702c645ce8960ab36c7968fd9f89bfc

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpd702c645ce8960ab36c7968fd9f89bfc"
* entry[=].resource = mpd702c645ce8960ab36c7968fd9f89bfc
                            
                    
Instance: bundlepackageleaflet-da-d702c645ce8960ab36c7968fd9f89bfc
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for enrylaze Package Leaflet for language da"
Description: "ePI document Bundle for enrylaze Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-d702c645ce8960ab36c7968fd9f89bfc"
* entry[0].resource = composition-da-d702c645ce8960ab36c7968fd9f89bfc

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpd702c645ce8960ab36c7968fd9f89bfc"
* entry[=].resource = mpd702c645ce8960ab36c7968fd9f89bfc
                            
                    



Instance: mpd702c645ce8960ab36c7968fd9f89bfc
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product enrylaze"
Description: "enrylaze"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/23/1747/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "enrylaze"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: d702c645ce8960ab36c7968fd9f89bfcListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "enrylaze"

* status = #current
* mode = #working

* title = "List of all ePIs associated with enrylaze"

* subject = Reference(mp1b4c40352fad33893373edfe0b062c8a)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#enrylaze "enrylaze"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-d702c645ce8960ab36c7968fd9f89bfc) // enrylaze en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-d702c645ce8960ab36c7968fd9f89bfc) // enrylaze da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-d702c645ce8960ab36c7968fd9f89bfc
InstanceOf: List

* insert d702c645ce8960ab36c7968fd9f89bfcListRuleset
    